000 | 01880 a2200541 4500 | ||
---|---|---|---|
005 | 20250514015009.0 | ||
264 | 0 | _c20020408 | |
008 | 200204s 0 0 eng d | ||
022 | _a1045-4403 | ||
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aDavda, J | |
245 | 0 | 0 |
_aAn update on angiogenesis therapy. _h[electronic resource] |
260 |
_bCritical reviews in eukaryotic gene expression _c2001 |
||
300 |
_a1-21 p. _bdigital |
||
500 | _aPublication Type: Journal Article; Review | ||
650 | 0 | 4 | _aAngiopoietin-1 |
650 | 0 | 4 | _aAnimals |
650 | 0 | 4 |
_aArteriosclerosis _xdrug therapy |
650 | 0 | 4 | _aChick Embryo |
650 | 0 | 4 | _aClinical Trials as Topic |
650 | 0 | 4 |
_aCollateral Circulation _xdrug effects |
650 | 0 | 4 |
_aCoronary Artery Disease _xdrug therapy |
650 | 0 | 4 | _aDrug Compounding |
650 | 0 | 4 | _aDrug Delivery Systems |
650 | 0 | 4 | _aDrug Evaluation, Preclinical |
650 | 0 | 4 |
_aEndothelial Growth Factors _xpharmacology |
650 | 0 | 4 |
_aEndothelium, Vascular _xdrug effects |
650 | 0 | 4 |
_aFibroblast Growth Factors _xpharmacology |
650 | 0 | 4 | _aForecasting |
650 | 0 | 4 | _aGenetic Therapy |
650 | 0 | 4 |
_aGrowth Substances _xadministration & dosage |
650 | 0 | 4 |
_aHindlimb _xblood supply |
650 | 0 | 4 | _aHumans |
650 | 0 | 4 |
_aHypotension _xchemically induced |
650 | 0 | 4 |
_aIschemia _xdrug therapy |
650 | 0 | 4 |
_aLymphokines _xpharmacology |
650 | 0 | 4 |
_aMembrane Glycoproteins _xpharmacology |
650 | 0 | 4 | _aMice |
650 | 0 | 4 |
_aNeovascularization, Pathologic _xchemically induced |
650 | 0 | 4 |
_aNeovascularization, Physiologic _xphysiology |
650 | 0 | 4 | _aRabbits |
650 | 0 | 4 | _aRats |
650 | 0 | 4 |
_aReceptors, Growth Factor _xdrug effects |
650 | 0 | 4 | _aVascular Endothelial Growth Factor A |
650 | 0 | 4 | _aVascular Endothelial Growth Factors |
700 | 1 | _aLabhasetwar, V | |
773 | 0 |
_tCritical reviews in eukaryotic gene expression _gvol. 11 _gno. 1-3 _gp. 1-21 |
|
999 |
_c11609604 _d11609604 |